Navigation Links
Researchers seek to make cavity-causing bacteria self-destruct
Date:1/2/2008

eate a library of mutant strains for the 2,000 known S. mutans genes, with each strain having just one of the 2,000 genes shut off. They will then subject the library to acid, for example, and see which strains thrive. Knowing which gene is missing from each strain, researchers will then be able to draw conclusions about each single genes contribution to not only to acid durability, but also to many aspects of the strep bacterias ability to survive and cause disease.

Down the road, the finished library will enable researchers to determine every bacterial protein involved in oral disease, to learn their exact structure and to tailor drugs that interfere with them, said Marquis. Identifying and turning off say the top four ways in which bacteria might try to resist treatment is the teams strategy.


'/>"/>

Contact: Greg Williams
Greg_Williams@urmc.rochester.edu
University of Rochester Medical Center
Source:Eurekalert

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. Stanford researchers find culprit in aging muscles that heal poorly
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Mayo Clinic researchers discover new diagnostic test for detecting infection in prosthetic joints
4. Bipolar disorder relapses halved by Melbourne researchers
5. Cell that triggers symptoms in allergy attacks can also limit damage, Stanford researchers find
6. High and mighty: first common height gene identified by researchers behind obesity gene finding
7. Researchers estimate about 9 percent of US children age 8 to 15 meet criteria for having ADHD
8. Majority of 2.4 Million U.S. Children With ADHD Not Diagnosed or Consistently Treated, According to New Gold Standard Study by Cincinnati Childrens Researchers
9. Researchers develop long-lasting growth hormone
10. Jefferson immunology researchers halt lethal rabies infection in brain
11. Purdue researchers develop technology to detect cancer by scanning surface veins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/16/2008)...e of Oral and Overall Health, HARRISBURG, Pa., Ma...d,Concordia Dental is celebrating National Smile M...and the British Dental Health Foundation to,promot... Beginning May 18,this year,s event is launching ... the largest independent international dental heal...
(Date:5/16/2008)...ociety of Clinical Oncology meeting in Chicago (Ab...out 25 percent of patients with colon cancer and i...ctal cancers will be staged. , This new study,...tion-based statistic registries from 1992 to 2004,...comes of patients with positive nodes (Stage III) ...
(Date:5/16/2008)...fit from calcitriol, an oral form , , FR...vitamin D may cut the risk of death for people wit...ut one quarter, a new study suggests. , During...se being treated with calcitriol, an oral form of ...th lowered by 26 percent when compared with those ...
(Date:5/16/2008)...g of the uterus (submucosal) are more likely to mo...embolization (UAE) but usually dont cause major co...udy included 49 patients with 140 fibroids who und...e study found that 39 of these were submucosal. Of...er UAE, said Sachit Verma, MD, lead author of the ...
Breaking Medicine News(10 mins):Health News:United Concordia Dental Celebrates National Smile Month 2Health News:Vitamin D Use Linked to Lower Mortality in Kidney Patients 2
... the growing problem of obesity in Australians by ...he study, published in the latest edition of The M...elp they wanted from their general practitioner (G... Levels of overweight and obesity in Australia ha...
...gricultural Research (ICAR) has announced the arri...loped by the High Security Animal// Disease Labora...ce in the whole of India that conducts tests for t...ector General Mangala Rai said, "Viral diseases, s...
...leagues, investigators from the Howard Hughes Medi... could help in identifying previously// unknown ge... The researchers by using a new technique, where i... which are present inside acute myeloid leukemia (...
...lowing a cardiac arrest at the work place, the emp... legal heirs// under the Workmen Compensation Act,...loyers' liability for compensation under Section 3...jit Pasayat and Justice L S Panta said "it has to ...
Other Medicine News:Health News:New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer 2Health News:New Technique Identifies Unknown Genetic Mutations That Can Cause Cancer 3
(Date:5/15/2008)...a newly cleared device to identify the, lipid cor...sociated with complications of c...wswire/ -- InfraReDx, Inc. today,announced that ph... have,successfully used its LipiScan(TM) Coronary ...atheterization. This is the first patient in the,w...
(Date:5/15/2008)...RNewswire/ -- Tigris Pharmaceuticals,Inc. announc...nd,Development Agreement (CRADA) with the National... and preclinical development of AFP-464, an,aminof...s converted to,metabolites which bind covalently t... This is part of a four-year CRADA encompassing m...
(Date:5/15/2008)... CEA Trial data reports in third quarter ... /- VIA Pharmaceuticals,In...ed on the development of,compounds for the treatme...,it has completed patient enrollment in its acute ...e of three Phase 2 trials investigating VIA-2291,...
(Date:5/14/2008)...Newswire-FirstCall/ -- Progen,Pharmaceuticals Limi...he,Company has resumed patient enrolment in the ph...ed polyamine analogue, PG-11047 (formerly CGC-1104... commenced development of PG-11047 - the lead clin... following its acquisition of,Cellgate, Inc earlie...
Breaking Medicine Technology:First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 2First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 3First Use in a Patient of The InfraReDx LipiScan(TM) Coronary Imaging System 4Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 2Tigris Pharmaceuticals Signs CRADA with the National Cancer Institute 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 2VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 3VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 4VIA Pharmaceuticals Completes Enrollment in Phase 2 Acute Coronary Syndrome (ACS) Trial 5Progen Resumes Phase 1 Development of Anti-Cancer Agent, PG-11047 2Study by Pittsburgh researchers identifies possible vaccine target for chlamydia 358 1Study by Pittsburgh researchers identifies possible vaccine target for chlamydia 358 2A step toward tissue engineered heart structures for children 355 1A step toward tissue engineered heart structures for children 355 2Microbiotic technology developed for microinjection of zebrafish embryos 1069 1Mathematics might save you a trip to the ER 1066 1Mathematics might save you a trip to the ER 1066 2
...-May 21, 2007 - Medical,professionals seeking to t...cquired gram-negative pneumonia may have a new wea...ct candidate being,developed by Nektar Therapeutic...rial evaluating the use of,NKTR-061 (Inhaled Amika...h hospital-acquired gram-negative pneumonia were,p...
...ed by FDA for long-term,maintenance treatment of C...bulized formoterol fumarate provides improved lung...anced patient quality of,life, and positive safety... presented at the,International Conference of the ...erforomist™ (formoterol fumarate),Inhalation...
Other Medicine Technology:Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 2Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 3Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 4Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 5Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 6Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 7Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 8Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 9Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 10Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference 11Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 2Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 3Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 4Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 5Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 6Clinical Trial Data for Perforomist (Formoterol Fumarate),Inhalation Solution Presented at International ATS Conference 7
...lumn of a 384 Well Plate at Once , To increase ef...need a pipettor that can adapt to the narrow well ...annel Impact pipettor., Available with Impact or ...tion was specifically designed to allow you to tra...
EnTrust family of ICDs provides a suite of features for total AT/AF co-morbidity management, including diagnostics to detect when your patient develops AT/AF, and both termination and intervention th
...e world leader in peel-away introducers. Our peel-...pacemaker and defibrillator lead implantation, cen...r temporary pacemaker insertions. The advanced des...udes the Di-Lock™ locking dilator and offers...
...ary Self-Expanding Stent System combines low-profi...y in one system. This .018" guide wire compatible ...ter compatibility in all diameters (5.0 - 10.0 mm)....018 system is offered in five stent lengths (28, ...
Medicine Products: